Clinical trial
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile…
NCT00211471 · Manhattan Eye, Ear & Throat Hospital, Other · Terminated
Key facts
| NCT number | NCT00211471 |
|---|---|
| Title | Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). |
| Official title | Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15mg.). |
| Lead sponsor | Manhattan Eye, Ear & Throat Hospital, Other |
| Collaborators | Alcon Research Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases |
| Intervention type | Drug |
| Interventions | anecortave acetate |
| Enrollment | 0 |
| Start date | Mar 1, 2002 |
| Completion | May 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | May 7, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: